Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Abstract
Objective null To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately-to-severely active rheumatoid arthritis (RA). null Methods null Data were pooled from 9 RA studies. Placebo comparison up to 24 weeks included data from 6 studies. Randomized dose comparison between baricitinib...
Paper Details
Title
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Published Date
Jul 1, 2019
Journal
Volume
71
Issue
7
Pages
1042 - 1055
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History